Alluvi, previously BI 4744, offers a significant advance in obesity care. This dual stimulator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide sites demonstrates remarkable results in clinical https://alluvi-healthcare490779.tusblogos.com/profile